This article only represents the author's own views.
It may still be at least two or three years away, and perhaps even further down the road. But there’s no mistaking the scent of money that provided a major boost for a group of novel cancer drug makers last month, including I-Mab (IMAB.US).
But it seems that scent is waxing and waning, based on I-Mab's recent share price volatility.
您已閱讀7%（385字），剩余93%（5361字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。